• Cell and Gene Therapy Access Challenges

  • 2024/12/04
  • 再生時間： 53 分
  • ポッドキャスト

Cell and Gene Therapy Access Challenges

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • In our second of three episodes in conjunction with members of ACCESS Forum, we engage with leading experts to uncover the multifaceted challenges of access and affordability in cell and gene therapies. Our conversation investigates how these treatments' innovative yet complex landscape leads to challenging regulatory pathways, pricing models, and reimbursement strategies.

    Alicia Silver, MPP, Head of Cell and Gene Therapy, ADVI Health
    Eric Faulkner, President, Passage Health Associates
    ADVI Health
    Alliance for Regenerative Medicine
    ARPA-H
    Bespoke Gene Therapy Consortium
    Blue Bird Bio
    Blue Cross Blue Shield
    Medicare DRG Rates
    NICE (National Institute for Health and Care Excellence)
    Novartis
    Passage Health Associates
    REMS Program
    Single Case Agreements
    Spark Therapeutics

    Medical terminology referenced in this episode:

    • Alzheimer's
    • Aspheresis
    • CAR T therapy
    • Hemophilia
    • Hepatitus C
    • Luxturna
    • Metachromatic leukodystrophy
    • Myeloablative Conditioning
    • Sickle Cell Disease
    • SMA treatment
    • Spinraza
    • Vaso Occlusive Crises
    • Zolgensma
    続きを読む 一部表示

あらすじ・解説

In our second of three episodes in conjunction with members of ACCESS Forum, we engage with leading experts to uncover the multifaceted challenges of access and affordability in cell and gene therapies. Our conversation investigates how these treatments' innovative yet complex landscape leads to challenging regulatory pathways, pricing models, and reimbursement strategies.

Alicia Silver, MPP, Head of Cell and Gene Therapy, ADVI Health
Eric Faulkner, President, Passage Health Associates
ADVI Health
Alliance for Regenerative Medicine
ARPA-H
Bespoke Gene Therapy Consortium
Blue Bird Bio
Blue Cross Blue Shield
Medicare DRG Rates
NICE (National Institute for Health and Care Excellence)
Novartis
Passage Health Associates
REMS Program
Single Case Agreements
Spark Therapeutics

Medical terminology referenced in this episode:

  • Alzheimer's
  • Aspheresis
  • CAR T therapy
  • Hemophilia
  • Hepatitus C
  • Luxturna
  • Metachromatic leukodystrophy
  • Myeloablative Conditioning
  • Sickle Cell Disease
  • SMA treatment
  • Spinraza
  • Vaso Occlusive Crises
  • Zolgensma
続きを読む 一部表示

Cell and Gene Therapy Access Challengesに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。